Recent News

• 04.21.2025 - Apellis Announces Craig Wheeler to Join the Board of Directors
• 04.21.2025 - Apellis Announces Craig Wheeler to Join the Board of Directors
• 04.21.2025 - Apellis Announces Craig Wheeler to Join the Board of Directors
• 04.01.2025 - Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
• 04.01.2025 - Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
• 04.01.2025 - Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 02.28.2025 - Apellis Pharmaceuticals, Inc. Fourth Quarter and Full Year 2024 Earnings Conference Call
• 02.28.2025 - Apellis Pharmaceuticals, Inc. Fourth Quarter and Full Year 2024 Earnings Conference Call

Recent Filings

• 04.21.2025 - 8-K Current report
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - 144 Report of proposed sale of securities
• 03.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.05.2025 - 144 Report of proposed sale of securities